Kodiak Sciences Inc. reports results for the quarter ended June 30 - Earnings Summary
Kodiak Sciences Inc. reports results for the quarter ended June 30 - Earnings Summary
Kodiak Sciences Inc. KOD.OQ reported a quarterly adjusted loss of $1.05 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.03. The mean expectation of five analysts for the quarter was for a loss of 96 cents per share. Wall Street expected results to range from -99 cents to -92 cents per share.
Reported revenue was zero; analysts expected zero.
Kodiak Sciences Inc.'s reported EPS for the quarter was a loss of $1.05.
The company reported a quarterly loss of $65.64 million.
Kodiak Sciences Inc. shares had risen by 11.4% this quarter and gained 55.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 0.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Kodiak Sciences Inc. is $61.50, about 29.4% above its last closing price of $43.41
This summary was machine generated from LSEG data August 13 at 08:10 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.96 | -1.05 | Missed |
Mar. 31 2026 | -1.01 | -0.94 | Beat |
Dec. 31 2025 | -1.05 | -1.04 | Beat |
Sep. 30 2025 | -1.03 | -1.16 | Missed |
Recent news on Kodiak Sciences
See all newsBrief: Kodiak Sciences Inc. Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX